Paediatric orodispersible lozenges produced by moulding process: quality and stability control

  1. Magariños-Triviño, María 123
  2. Monzón-Rodríguez, Cecilia 1
  3. Caiazzo-Lima, José Andrés 1
  4. Santoveña-Estévez, Ana 12
  5. Fariña, José B. 12
  1. 1 Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia , 73033 University of La Laguna , La Laguna , Tenerife , Spain
  2. 2 Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias , 73033 University of La Laguna , La Laguna , Tenerife , Spain
  3. 3 Programa de Doctorado Ciencias Médicas y Farmacéuticas, Desarrollo y Calidad de Vida , 73033 University of La Laguna , La Laguna , Tenerife , Spain
Mostrar afiliaciones +
Revista:
Pharmaceutical Technology in Hospital Pharmacy

ISSN: 2365-2411,  2365-242X

Año de publicación: 2024

Volumen: 9

Número: 1

Tipo: Artículo

DOI: 10.1515/PTHP-2023-0012 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Pharmaceutical Technology in Hospital Pharmacy

Referencias bibliográficas

  • Ward, RM, Benjamin, DK, Davis, JM, Gorman, RL, Kauffman, R, Kerans, GL, et al.. The need for pediatric drug development. J Pediatr 2018;192:13–21. https://doi.org/10.1016/j.jpeds.2017.08.011.
  • Vallet, T, Elhamdaoui, O, Berraho, A, Cherkaoui, LO, Kriouile, Y, Mahraoui, C, et al.. Medicines acceptability in hospitalized children: an ongoing need for age-appropriate formulations. Pharmaceutics 2020;12:1–12. https://doi.org/10.3390/pharmaceutics12080766.
  • Kurbanoglu, S, Uslu, B, Ozkan, SA. Carbon-based nanostructures for electrochemical analysis of oral medicines. In: Andronescu, E, Grumezescu, AM, editors. Nanostructures for oral medicine. Ankara: Elsevier; 2017:885–938 pp.
  • Lura, A, Luhn, O, Suarez Gonzales, J, Breitkreutz, J. New orodispersible mini-tablets for paediatric use – a comparison of isomalt with a mannitol based co-processed excipient. Int J Pharm 2019;572:118804. https://doi.org/10.1016/j.ijpharm.2019.118804.
  • Suárez-González, J, Magariños-Triviño, M, Díaz-Torres, E, Cáceres-Pérez, A, Santoveña-Estévez, A, Fariña, JB. Individualized orodispersible pediatric dosage forms obtained by molding and semi-solid extrusion by 3D printing: a comparative study for hydrochlorothiazide. J Drug Deliv Sci Technol 2021;66:102884. https://doi.org/10.1016/j.jddst.2021.102884.
  • European Pharmacopoeia (EP). Oromucosal preparations 01/2021:01807, 11.2 ed. France, Strasbourg: Council of Europe; 2021.
  • United States Pharmacopeia (USP). General chapter pharmaceutical dosage forms (1551), ed. Rockville, Maryland, USA: The United States Pharmacopoeia Convention; 2021.
  • Montero-Padilla, S, Velaga, S, Morales, JO. Buccal dosage forms: general considerations for pediatric patients. AAPS PharmSciTech 2017;18:273–82. https://doi.org/10.1208/s12249-016-0567-2.
  • Malkawi, WA, AlRafayah, E, AlHazabreh, M, AbuLaila, S, Al-Ghananeem, AM. Formulation challenges and strategies to develop pediatric dosage forms. Children 2022;9:488. https://doi.org/10.3390/children9040488.
  • Strepsils. Sore throat relief lozenges for children. [Web page]. Strepsils; 2020. https://www.strepsilsme.com/products/strepsils/junior/ [Accessed 25 Sep 2023].
  • Pattanayak, D, Das, S. Formulation development and optimization of medicated lozenges for pediatric use. Int J Pharmaceut Sci Res 2012;3:138–40. https://doi.org/10.13040/IJPSR.0975-8232.3(1.
  • Mulla, UN, Salunkhe, A. Medicated lozenges: as an easy to use for pediatric and geriatric patients. Int J Creativ Res Thoughts 2021;9:466–71.
  • Comité de Medicamentos de la Asociación Española de Pediatría. Ficha de Hidroclorotiazida [internet monograph]. Madrid: Asociación Española de Pediatría; 2022. Available from: https://www.aeped.es/comite-medicamentos/pediamecum/hidroclorotiazida.
  • Choi, JN, Lee, JS, Shin, JI. Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. Acta Paediatr 2011;100:71–4. https://doi.org/10.1111/j.1651-2227.2011.02191.x.
  • Takagi, T, Ramachandran, C, Bermejo, M, Yamashita, S, Yu, LX, Amidon, GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006;3:631–43. https://doi.org/10.1021/mp0600182.
  • Agencia Española de Medicamentos y Productos Sanitarios, (AEMPS). Centro de información de medicamentos (CIMA) [internet database]; 2017. https://cima.aemps.es/cima/publico/home.html [Accessed 25 Sep 2023].
  • Food and Drug Administration. Drug approvals and databases. FDA [internet database]; 2022. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases [Accessed 25 Sep 2023].
  • World Health Organization (WHO). Child growth standards. Standards [Webpage]. WHO; 2023. https://www.who.int/tools/child-growth-standards/standards/weight-for-age [Accessed 25 Sep 2023].
  • World Health Organization. Model lists of essential medicines for children – 8th list. [Webpage]. WHO; 2021. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03 [Accessed 25 Sep 2023].
  • Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics The National Institutes of Health (NIH). [Webpage]. NIH; 2020. https://www.nichd.nih.gov/sites/default/files/inline-files/2020PriorityListFeb20.pdf [Accessed 25 Sep 2023].
  • Sam, T, Ernest, TB, Walsh, J, Williams, JL. European Paediatric Formulation Initiative (EuPFI). A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms – an application for paediatric dosage form selection. Int J Pharm 2012;435:115–23. https://doi.org/10.1016/j.ijpharm.2012.05.024.
  • Santoveña, A, Hernández-Paiz, Z, Fariña, JB. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int J Pharm 2012;423:360–4. https://doi.org/10.1016/j.ijpharm.2011.11.034.
  • Agencia Española de Medicamentos y Productos Sanitarios. Suspensión oral de hidroclorotiazida 2 mg/ml FN/2014/FMT/022 [internet monograph]. Madrid: BOE; 2014. https://www.aemps.gob.es/formulario-nacional/monografias/formulas-magistrales-tipificadas-pediatricas/fn_2014_fmt_022.pdf?x85339 [Accessed 25 Sep 2023].
  • European Pharmacopoeia (EP). Tablets 01/2018:0478, 11.2 ed. France, Strasbourg: Council of Europe; 2018.
  • European Pharmacopoeia (EP). 2.9.5. Uniformity of mass of single-dose preparations 04/2023:20905, 11.2 ed. France, Strasbourg: Council of Europe; 2023.
  • European Pharmacopoeia (EP). 2.9.40. Uniformity of dosage units 04/2017:20940, 11.2 ed. France, Strasbourg: Council of Europe; 2023.
  • European Pharmacopoeia (EP). 2.9.1. Disintegration of table 01/2022:2090, 11.2 ed. France, Strasbourg: Council of Europe; 2022.
  • The International Council of Harmonisation (ICH). Stability testing of new drug substances and products Q1A(R2). [internet monograph]. London: European Medicines Agency (EMA); 2003. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf [Accessed 25 Sep 2023].
  • Carvalho, M, Almeida, IF. The role of pharmaceutical compounding in promoting medication adherence. Pharmaceuticals 2022;15:1091. https://doi.org/10.3390/ph15091091.